

Wayne O Miles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3379415/publications.pdf>

Version: 2024-02-01

27
papers

803
citations

687363

13
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

1658
citing authors

#	ARTICLE	IF	CITATIONS
1	Pumilio facilitates miRNA regulation of the E2F3 oncogene. <i>Genes and Development</i> , 2012, 26, 356-368.	5.9	140
2	Modeling tumor invasion and metastasis in <i>Drosophila</i> . <i>DMM Disease Models and Mechanisms</i> , 2011, 4, 753-761.	2.4	99
3	Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylation. <i>Genes and Development</i> , 2015, 29, 1875-1889.	5.9	76
4	Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. <i>Cancer Discovery</i> , 2020, 10, 1296-1311.	9.4	49
5	Beyond CLIP: advances and opportunities to measure RBP-RNA and RNA-RNA interactions. <i>Nucleic Acids Research</i> , 2019, 47, 5490-5501.	14.5	48
6	Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation. <i>Cancer Research</i> , 2016, 76, 7231-7241.	0.9	47
7	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. <i>Nature Communications</i> , 2019, 10, 5157.	12.8	46
8	Medea SUMOylation restricts the signaling range of the Dpp morphogen in the <i>Drosophila</i> embryo. <i>Genes and Development</i> , 2008, 22, 2578-2590.	5.9	45
9	Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine—Specific Cancer Targeting with Undetectable Toxicity. <i>Chemical Reviews</i> , 2021, 121, 7398-7467.	47.7	45
10	Non-coding and Coding Transcriptional Profiles Are Significantly Altered in Pediatric Retinoblastoma Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 221.	2.8	27
11	Posttranscriptional gene expression control by <i>NANOS</i> is upregulated and functionally important in <i>pR</i> deficient cells. <i>EMBO Journal</i> , 2014, 33, 2201-2215.	7.8	25
12	Transcriptional targeting of oncogene addiction in medullary thyroid cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	19
13	Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges. <i>JCO Precision Oncology</i> , 2022, 6, e2100211.	3.0	19
14	Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1519-1529.	1.1	17
15	Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer. <i>Cancers</i> , 2020, 12, 2616.	3.7	16
16	<i>In Vivo</i> Regulation of E2F1 by Polycomb Group Genes in <i>Drosophila</i> . <i>G3: Genes, Genomes, Genetics</i> , 2012, 2, 1651-1660.	1.8	14
17	The LSD1 Family of Histone Demethylases and the Pumilio Posttranscriptional Repressor Function in a Complex Regulatory Feedback Loop. <i>Molecular and Cellular Biology</i> , 2015, 35, 4199-4211.	2.3	12
18	Metabolite systems profiling identifies exploitable weaknesses in retinoblastoma. <i>FEBS Letters</i> , 2019, 593, 23-41.	2.8	11

#	ARTICLE	IF	CITATIONS
19	RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. <i>Frontiers in Genetics</i> , 2018, 9, 170.	2.3	10
20	Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 535.	4.1	6
21	Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. <i>Npj Precision Oncology</i> , 2022, 6, 29.	5.4	6
22	Pumilio and nanos RNA-binding proteins counterbalance the transcriptional consequences of RB1 inactivation. <i>Molecular and Cellular Oncology</i> , 2014, 1, e968074.	0.7	3
23	RB-loss puts focus on Myc. <i>Nature Cell Biology</i> , 2015, 17, 968-969.	10.3	3
24	Slit2/Robo1 signaling inhibits smallâ€cell lung cancer by targeting β -catenin signaling in tumor cells and macrophages. <i>Molecular Oncology</i> , 2023, 17, 839-856.	4.6	3
25	RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment. <i>Translational Oncology</i> , 2021, 14, 101197.	3.7	2
26	Mass COVID-19 patient screening using UvsX and UvsY mediated DNA recombination and high throughput parallel sequencing. <i>Scientific Reports</i> , 2022, 12, 4082.	3.3	2
27	Integrated multi-omics analysis of RB-loss identifies widespread cellular programming and synthetic weaknesses. <i>Communications Biology</i> , 2021, 4, 977.	4.4	1